Provided by Tiger Fintech (Singapore) Pte. Ltd.

C4 Therapeutics, Inc.

1.40
+0.150012.00%
Post-market: 1.410.0100+0.71%19:55 EDT
Volume:1.50M
Turnover:2.10M
Market Cap:99.39M
PE:-0.92
High:1.49
Open:1.24
Low:1.20
Close:1.25
Loading ...

Owner of now-defunct Le Matin Patisserie collaborating with restaurant Air CCCC on new pastry menu

CNA
·
15 Nov 2024

C4 Therapeutics Announces First Patient Dosed in Cft8919 Clinical Trial

THOMSON REUTERS
·
06 Nov 2024

C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial

GlobeNewswire
·
06 Nov 2024

C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin’s Lymphoma at the American Society of Hematology (ASH) Annual Meeting

GlobeNewswire
·
05 Nov 2024

CCCG Real Estate Plans to Acquire CCCC Services for 700 Million Yuan

MT Newswires Live
·
04 Nov 2024

China Communications Construction Co. Announces Equity Sale

TIPRANKS
·
01 Nov 2024

C4 Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.
·
01 Nov 2024

Analysts’ Top Healthcare Picks: C4 Therapeutics (CCCC), Alnylam Pharma (ALNY)

TIPRANKS
·
01 Nov 2024

C4 Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary

Reuters
·
01 Nov 2024

BRIEF-C4 Therapeutics Files For Resale Of Up To 4.9 Mln Shares By Selling Stockholder

Reuters
·
01 Nov 2024

BRIEF-C4 Therapeutics Files For Mixed Shelf Of Up To $400 Mln

Reuters
·
01 Nov 2024

C4 Therapeutics files $400M mixed securities shelf

TIPRANKS
·
01 Nov 2024

C4 Therapeutics files to sell 4.87M shares of common stock for holders

TIPRANKS
·
01 Nov 2024

C4 Therapeutics Inc Files for Resale of up to 4.9 Mln Shares of Common Stock by the Selling Stockholder - SEC Filing

THOMSON REUTERS
·
01 Nov 2024

C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Tops Revenue Estimates

Zacks
·
31 Oct 2024

C4 Therapeutics reports Q3 EPS (35c), consensus (38c)

TIPRANKS
·
31 Oct 2024

BRIEF-C4 Therapeutics Q3 EPS USD -0.35 Vs. IBES Estimate USD -0.38

Reuters
·
31 Oct 2024

C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

THOMSON REUTERS
·
31 Oct 2024

C4 Therapeutics Q3 EPS USD -0.35 VS. Ibes Estimate USD -0.38

THOMSON REUTERS
·
31 Oct 2024

C4 Therapeutics Q3 Revenue USD 15.4 Million VS. Ibes Estimate USD 4.6 Million

THOMSON REUTERS
·
31 Oct 2024